AMB-FUBINACA is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors, with Kᵢ values of 10.04 nM at CB₁ and 0.786 nM at CB₂ and EC₅₀ values of 0.5433 nM at CB₁ and 0.1278 nM at CB₂, and has been sold online as a designer drug.
MDMB-CHMICA (also incorrectly known as MMB-CHMINACA) is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug.While MDMB-CHMICA was initially sold under the name “MMB-CHMINACA”, the compound corresponding to this code name (i.e. the isopropyl instead of t-butyl analogue of MDMB-CHMINACA) has been identified on the designer drug market in 2015 as AMB-CHMINACA.
NM-2201 is an indole-based synthetic cannabinoid that presumably has similar properties to the closely related 5F-PB-22 and NNE1, which are both full agonists and unselectively bind to CB₁ and CB₂ receptors with low nanomolar affinity.
SDB-005 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. It is presumed to be an agonist of the CB₁ and CB₂ cannabinoid receptors. SDB-005 is the indazole core analog of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.